8.17
-0.13(-1.57%)
Currency In USD
| Previous Close | 8.3 |
| Open | 8.3 |
| Day High | 8.3 |
| Day Low | 8.11 |
| 52-Week High | 8.85 |
| 52-Week Low | 3.68 |
| Volume | 96,011 |
| Average Volume | 227,335 |
| Market Cap | 302.5M |
| PE | -5.56 |
| EPS | -1.47 |
| Moving Average 50 Days | 7.2 |
| Moving Average 200 Days | 6.47 |
| Change | -0.13 |
If you invested $1000 in Lifecore Biomedical, Inc. (LFCR) 10 years ago, it would be worth $581.49 as of July 14, 2025 at a share price of $8.17. Whereas If you bought $1000 worth of Lifecore Biomedical, Inc. (LFCR) shares 5 years ago, it would be worth $934.78 as of July 14, 2025 at a share price of $8.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer
GlobeNewswire Inc.
Jun 17, 2025 11:00 AM GMT
Represents Continuation of Long-Running Partnership Focused on Supporting Advancement of Novel Ophthalmic Therapeutic Toward CommercializationCHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale
GlobeNewswire Inc.
Jun 12, 2025 11:00 AM GMT
Fortifies Balance Sheet and Reinforces Disciplined Capital Management ApproachCHASKA, Minn., June 12, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organiza
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer
GlobeNewswire Inc.
May 27, 2025 11:00 AM GMT
Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations Will Leverage Deep Pharma Services Expertise as Leader of Lifecore’s Sales Organization Focuse